Sinomenine Versus NSAIDs for the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

Abstract

Sinomenine (SIN), an alkaloid isolated from Caulis sinomenii, has been used in the treatment of rheumatoid arthritis (RA) clinically. This study aimed to systematically evaluate the efficacy and safety of SIN by a comparison between SIN and non-steroidal anti-inflammatory drugs (NSAIDs). Forty-three electronic databases were systematically searched. The quality of eligible trials was assessed by Jadad’s scale. Revman 5.0 software was used for data syntheses and meta-analyses. The results showed that (i) of the 121 potential studies identified, 10 clinical trials involving 1185 patients met the inclusion criteria; (ii) improved patients and rheumatoid factor disappearance patients after SIN treatments were significantly more than those treated by NSAIDs (P < 0.00001 and P = 0.008); (iii) compared with NSAIDs, SIN was more effective in amelioration of morning stiffness (P < 0.00001), painful joints (P = 0.03), and erythrocyte sedimentation rate (P < 0.00001), but there was no significant difference between the two remedies in the treatment of swollen joints, grip strength, and C-reactive protein (P > 0.05); and (iv) adverse events occurred less frequently in the digestive system during SIN treatment than during NSAID treatment (P = 0.0003) but occurred more frequently in the dermatomucosal system with SIN treatment (P = 0.03), while adverse events of the nervous system were similar for both treatments (P = 0.31). In conclusion, SIN may be a valuable remedy to treat RA clinically, although current evidence needs to be further verified by more high-quality trials.

Key words

sinomenine - herbal medicine - rheumatoid arthritis - systematic review - meta-analysis

References

• 1 Smolen J S, Aletaha D, Machold K P. Therapeutic strategies in early rheumatoid arthritis.  Best Pract Res Clin Rheumatol. 2005;  19 163-77
• 2 Pugner K M, Scott D I, Holmes J W, Hieke K. The costs of rheumatoid arthritis: an international long-term view.  Semin Arthritis Rheum. 2000;  29 305-20
• 3 Ernst E, Chrubasik S. Phyto-anti-inflammatories. A systematic review of randomized, placebo-controlled, double-blind trials.  Rheum Dis Clin North Am. 2000;  26 13-27
• 4 Anon Caulis sinomenii. In: Chinese Pharmacopoeia Committee, editors. 2005 Chinese Pharmacopoeia, Vol. 1. Beijing; Chinese Chemical Industry Press 2005: 135
• 5 Cai X, Zhou H, Xu H X, Liu L. Herbal medicine in the treatment of rheumatoid arthritis: an overview of clinical research.  Chin J Tradit Chin Med Pharm. 2005;  20 309-11
• 6 Cochrane hand search manual. (serial on the Internet). Available at http://www.cochrane.org/resources/hsmpt1.htm Accessed February 19, 2008
• 7 Arnett F C, Edworthy S M, Bloch D A, McShane D J, Fries J F, Cooper N S. et al . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.  Arthritis Rheum. 1988;  31 315-24
• 8 Du Y X, Lei C B, Chen J Q, Zhang X M, Zhang Y, Wang G Q. et al . A comparative study or the literature included in the five authoritative domestic databases of Chinese biomedical journals.  J Prey Med Inf. 2006;  22 162-6
• 9 Jadad A R, Moore R A, Carroll D, Jenkinson C, Reynolds D J, Gavaghan D J. et al . Assessing the quality of reports of randomized clinical trials: is blinding necessary?.  Control Clin Trials. 1996;  17 1-12
• 10 Yang D C, Zheng X C. The observation on curative effects of sinomenine in treatment of rheumatoid arthritis.  Drug Eval. 2005;  2 152-3
• 11 Yang X H, Yang J Y. Therapeutic effects of sinomenine in the treatment of rheumatoid arthritis: a report of 118 cases.  J Chin Physician. 2003;  5 297-8
• 12 Zhou S H, Zhao Y. The clinical observation of sinomenine in treatment of rheumatoid arthritis: a report of 43 cases.  Shanxi J Tradit Chin Med. 2003;  19 19-20
• 13 Chen Z D. The effects of sinomenine and diclofenac tablets in treatment of rheumatoid arthritis: a report of 60 cases.  Herb Med. 1999;  18 309
• 14 Hu X J, Wu D H, Tan G B, Hu G H, Sun K W. Therapeutic effects of sinomenine in the treatment of 428 patients with rheumatoid and rheumatic arthritis.  Hunan J Tradit Chin Med. 1999;  15 11-3
• 15 Zhang Q. Clinical observations of sinomenine in the treatment of rheumatoid arthritis: a report of 52 cases.  Fujian J Tradit Chin Med. 1998;  29 17-8
• 16 Wu X Y, Ye Z Z, Xu Y H. Sinomenine in treatment of 31 patients with juvenile rheumatoid arthritis.  J Appl Clin Pediatr. 1997;  12 330-1
• 17 Zhou D Q. A clinical study of sinomenine in the treatment of 152 cases with rheumatoid arthritis.  Chin Tradit Pat Med. 1996;  18 28-9
• 18 Ye B Z. Clinical observations of sinomenine in the treatment of rheumatoid and rheumatic arthritis: a report of 62 cases.  Hunan J Tradit Chin Med. 1995;  11 15-6
• 19 Liu Z X, Liu Y. Curative effects of sinomenine in the treatment of arthritis: a report of 105 cases.  Hunan J Tradit Chin Med. 1993;  9 10-2
• 20 Felson D T, Anderson J J, Boers M, Bombardier C, Furst D, Goldsmith C. et al . American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.  Arthritis Rheum. 1995;  38 727-35
• 21 Liu Q, Zhou L L, Li R. The general situation of sinomenine studies.  Chin Tradit Herb Drugs. 1997;  28 247-9
• 22 Simon L S. The COX-2 inhibitors: a reasoned review of the data.  Swiss Med Wkly. 2005;  135 419-24
• 23 Liu L, Buchner E, Beitze D, Schmidt-Weber C B, Kaever V, Emmrich F. et al . Amelioration of rat experimental arthritides by treatment with the alkaloid sinomenine.  Int J Immunopharmacol. 1996;  18 529-43
• 24 Lazzaroni M, Bianchi Porro G. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations.  Aliment Pharmacol Ther. 2004;  20 48-58
• 25 Mitchell J A, Warner T D. Cyclo-oxygenase-2: pharmacology, physiology, iochemistry and relevance to NSAID therapy.  Br J Pharmacol. 1999;  128 1121-32
• 26 Wang W J, Wang P X, Li X J. The effects of sinomenine on cyclooxygenase activity and COX-2 mRNA expression in human peripheral monocytes.  Chin J Chin Mater Med. 2003;  28 352-5
• 27 Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe P A, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.  Lancet. 2004;  364 2021-9
• 28 Van Doornum S, McColl G, Wicks I P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?.  Arthritis Rheum. 2002;  46 862-73
• 29 Homma M. ACR preliminary definition of improvement in rheumatoid arthritis.  Ryumachi. 1996;  36 891-900
• 30 Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I. et al . Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review.  Rheumatology (Oxford). 2002;  41 1346-56